AVEO Stock Recent News

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Here is how AVEO Pharmaceuticals (AVEO) and Merit Medical (MMSI) have performed compared to their sector so far this year.

AVEO Oncology (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Does AVEO Pharmaceuticals (AVEO) have what it takes to be a top stock pick for momentum investors? Let's find out.

AVEO (AVEO) delivered earnings and revenue surprises of 43.75% and 1.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Oncology's (AVEO) third-quarter earnings is expected to reflect strong Fotivda sales. The company is likely to beat the Zacks Consensus Estimate.

Here is how AVEO Pharmaceuticals (AVEO) and Akero Therapeutics, Inc. (AKRO) have performed compared to their sector so far this year.

LG Chem is buying AVEO Oncology for $566 million. These are the details.

Aveo Pharmaceuticals Inc (NASDAQ:AVEO) stock is soaring today, up 40.7% at $14.74 at last glance, after news that South Korean chemical company LG Chem plans to buy the biopharmaceutical name for $15 per share, or roughly $566 million, in an all-cash deal.